US equities |
MU $965.25 ▲+3.93% META $612.74 ▼-1.20% TSLA $401.65 ▼-1.43% SPCX $143.69 ▼-3.29% NVDA $216.72 ▼-0.56% SNDK $1,378.94 ▲+5.68% GOOGL $324.62 ▲+1.26% SKHY $164.09 ▲+12.89%
FinancialContent

bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

3.040 +0.080 (+2.70%)
Delayed Quote Updated: 1:22 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bioAffinity Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
These stocks are making the most noise in today's session. ↗
Via Chartmill
Which stocks have an unusual volume on Friday? ↗
Via Chartmill
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
News headline image
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Third Quarter 2025 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains? ↗
bioAffinity Technologies' stock surged after a patent notice and Nasdaq compliance update but slipped in after-hours trading. 
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
What's Driving bioAffinity Technologies' Big Pre-Market Surge? ↗
bioAffinity Technologies shares surged over 20% pre-market following a strong third-quarter sales update for its lung cancer diagnostic test. 
Via Benzinga
News headline image
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Energy Fuels, Firefly Aerospace And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >